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ABSTRACT
Previously, we have demonstrated the presence of anti-calcium-sensing receptor (CaSR) antibodies in patients with autoimmune
polyglandular syndrome type 1 (APS1), a disease that is characterized in part by hypoparathyroidism involving hypocalcemia,
hyperphosphatemia, and low serum levels of parathyroid hormone. The aim of this study was to define the binding domains on
the CaSR of anti-CaSR antibodies found in APS1 patients and in one patient suspected of having autoimmune hypocalciuric
hypercalcemia (AHH). A phage-display library of CaSR peptides was constructed and used in biopanning experiments with patient
sera. Selectively enriched IgG-binding peptides were identified by DNA sequencing, and subsequently, immunoreactivity to these
peptideswasconfirmedinELISA.Anti-CaSRantibodybindingsitesweremappedtoaminoacidresidues41–69,114–126,and171–195at
the N-terminal ofthe extracellular domain ofthe receptor. Themajor autoepitope was localized in the 41–69 amino acidsequence of the
CaSR with antibody reactivity demonstrated in 12 of 12 (100%) APS1 patients with anti-CaSR antibodies and in 1 AHH patient with anti-
CaSRantibodies.Minorepitopeswerelocatedinthe114–126and171–195aminoaciddomains,withantibodyreactivityshownin5of12
(42%) and 4 of 12 (33%) APS1 patients, respectively. The results indicate that epitopes for anti-CaSR antibodies in the AHH patient and in
the APS1 patients who were studied are localized in the N-terminal of the extracellular domain of the receptor. The present work has
demonstrated the successful use of phage-display technology in the discovery of CaSR-specific epitopes targeted by human anti-CaSR
antibodies.  2010 American Society for Bone and Mineral Research.
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Introduction
A
complex homeostatic system involvingthe interplay ofthe
bones, kidneys, and intestines has evolved to maintain
extracellular concentrations of calcium within a relatively narrow
range.
(1) The primary regulator of this system is parathyroid
hormone (PTH), the release of which is initiated by signals from
the calcium-sensing receptor
(2) (CaSR) in response to circulating
calcium levels. When the CaSR is activated by elevated calcium, it
signals the retention of PTH in the parathyroid cells. Conversely,
when the CaSR is not activated owing to low calcium levels, it
does not signal, and PTH is released. Over- and underproduction
of PTH gives rise to hyper- and hypocalcemia, respectively,
because the efflux of calcium from bone, the reabsorption of
urinary calcium, and the uptake of dietary calcium are variously
affected.
(1)
Autoimmune polyendocrine syndrome type 1 (APS1) is a rare
autosomal recessive disorder
(3) caused by mutations in the
autoimmune regulator (AIRE) gene
(4,5) and is characterized by
multiple organ-specific autoimmunity and ectodermal manifes-
tations.
(3,6) In the majority of cases, disease components include
mucocutaneous candidiasis, hypoparathyroidism, and Addison’s
disease, with type 1 diabetes mellitus, alopecia, vitiligo,
autoimmune hepatitis, and pernicious anemia occurring less
frequently. Patients typically display a wide variety of auto-
antibodies against enzymes found in the affected organs,
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132including 21-hydroxylase, 17-a-hydroxylase, and side-chain
cleavage enzyme, all of which are present in the adrenal
cortex,
(7–9) as well as pancreatic glutamic acid decarboxylase 65
and tyrosine phosphatase-like protein IA-2, which are also
prevalent in autoimmune type 1 diabetes mellitus.
(10,11)
As part of APS1, hypoparathyroidism occurs in 80% of patients
and is characterized by hypocalcemia, hyperphosphatemia, and
low serum levels of PTH. Early reports suggested that the
clinical symptoms and biochemical manifestations of hypopar-
athyroidism could result from humoral immune responses to
parathyroid cells.
(12,13) Subsequently, the G protein-coupled
CaSR
(2) was identified as a parathyroid autoantigen in patients
with APS1,
(14–16) as well as in individuals affected by isolated
autoimmune hypoparathyroidism
(14,15,17,18) and autoimmune
hypocalciuric hypercalcemia (AHH).
(19–21) Earlier studies have
indicated that patient anti-CaSR antibodies recognize epitopes
in the extracellular domain,
(14–16) but only in a few cases has
binding to specific CaSR peptides been demonstrated.
(18–20)
The aim of this study was to define the binding sites of anti-
CaSR antibodies detected in a cohort of patients with APS1 in a
previous study.
(16) In addition, the epitopes recognized by anti-
CaSR antibodies in a single patient with putative AHH were to be
determined. To achieve this objective, peptide phage-display
technology was employed.
Materials and Methods
Patients and controls
The study was approved by the Ethics Committee of Tampere
University Hospital, Tampere, Finland, and the APS1 patients
participated inthe study after obtaininginformed consent, given
either by the patient or by the patient’s parents. The study of
the patient with putative AHH was approved by the Institu-
tional Review Board of Partners Health Care, Boston, MA, USA,
and serum was obtained from the patient after obtaining
written informed consent. Sera were stored at  208C prior to
use.
Fourteen APS1 patients (7 male, 7 female; mean age 18 years,
with a range of 10 to 47 years) were studied. All patients had
Addison’s disease and mucocutaneous candidiasis. Thirteen
patients had hypoparathyroidism. Other autoimmune diseases
present were premature ovarian failure (5), alopecia (3), vitiligo
(5), type 1 diabetes mellitus (3), autoimmune hypothyroidism (1),
and pernicious anemia (2). All patients carried mutations in both
alleles of the AIRE gene.
(5) In our previous study, anti-CaSR
antibodies were detected using immunoprecipitation assays in
12 of these patients.
(16)
One AHH patient (female, age 73 years) with a positive
antinuclear antibody titer of 1:5120 and anti-ribonuclear protein
antibodies developed hypercalcemia, an elevated level of intact
PTH and marked hypocalciuria (10 to 40 mg/24 h), prompting
investigation of possible AHH. Three separate serum samples
were available, and anti-CaSR antibodies were detected in
each of them (unpublished data) using immunoprecipitation
assays.
(16)
Twenty healthy individuals (9 male, 11 female; mean age
32 years, with range 24 to 48 years) who had no present or past
history of autoimmune disorders were included as controls. No
individual had anti-CaSR antibodies when tested in immuno-
precipitation assays.
(16)
Specific anti-CaSR antibodies
Anti-CaSR rabbit polyclonal antibody against a synthetic peptide
corresponding to amino acids 12–27 of the rat CaSR was
purchased from Alexis Biochemicals (Nottingham, UK). The
antibody has cross-reactivity with the human CaSR. Anti-CaSR
mouse monoclonal antibody against a synthetic peptide
corresponding to amino acids 214–235 of the human CaSR
was obtained from Acris Antibodies (Herford, Germany).
Phage-display library construction
Vector pComb3
(22) was used to construct a phage-display library
of CaSR peptides. The vector is designed to allow the expression
of cloned DNA fragments and the subsequent surface exposure
of the peptides encoded therein on phage particles. For surface
expression, DNA fragments are required to be cloned in frame
with the PelB leader peptide and the gene III phage coat protein
present in pComb3 at the N- and C-terminal, respectively.
To construct a CaSR cDNA fragment library in pComb3, full-
length CaSR cDNA was prepared from pcCaSR-FLAG
(16) by
restriction of the plasmid with KpnI (Promega) and XbaI
(Promega). The resulting 3255-bp CaSR cDNA fragment was
separated by agarose gel electrophoresis
(23) and purified using a
Wizard PCR Preps DNA Purification System (Promega, South-
ampton, UK). Random 100- to 300-bp fragments of CaSR cDNA
were prepared by digestion with DNAse I in a reaction
containing: 1 mg CaSR cDNA, 1 unit DNAse I (Promega), and
DNAse I buffer (Promega). The reaction was incubated at room
temperature for 15 minutes and then terminated by the addition
of 50 mM EDTA (pH 8.0). The DNA fragments were purified using
a Wizard PCR Preps DNA Purification System and treated with T4
DNA polymerase (Promega) according to the manufacturer’s
protocol to create blunt ends. After further purification, the
fragments were ligated into the EcoRV restriction site of pComb3
using standardmethods.
(23)TheCaSRcDNAfragment librarywas
recovered by electroporation of Escherichia coli XL1-Blue cells
(Stratagene, La Jolla, CA, USA), as described by the manufacturer.
The library size was estimated by plating out samples of
electroporated cells onto Luria-Bertani (LB) agar
(23) containing
100 mg/mL ampicillin and 10 mg/mL tetracycline.
To prepare the CaSR peptide phage-display library, the
electroporated cells were incubated for 1 hour at 378C before
superinfection with 1 10
12 plaque-forming units of VCMS13
helper phage (Stratagene) at 378C for 15 minutes. The culture
subsequently was transferred to 100 mL of LB medium
(23) sup-
plemented with 100 mg/mL ampicillin, 10 mg/mL tetracycline,
and 10 mg/mL kanamycin. After overnight incubation at 378C,
the culture was centrifuged and phage precipitated from the
supernatant with 0.2 volumes of 20% (w/v) polyethylene glycol
4000/2.5 M NaCl. The phage were resuspended in 2 to 3 mL
phosphate-buffered saline (pH 7.4; PBS, Sigma, Poole, UK) and
stored at  208C. The phage titer was determined by infecting
log-phase E. coli XL1-Blue with an aliquot of the phage-display
library and then plating out samples onto selective LB agar.
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For biopanning experiments, human sera or animal anti-CaSR
antibodies (10-mL aliquots) were applied to the wells of Corning
polystyrene 96-well microtiter plates (Bibby Sterilin, Ltd., Mid
Glamorgan, UK) in 50 mL of buffer containing 1.5 mM Na2CO3,
3.5 mM NaHCO3, and 3.0 mM NaN3 (pH 9.2). Plates were
incubated at room temperature for 2 hours to allow antibody
binding before washing with PBS/0.05% (w/v) Tween 20 (PBS/
Tween). To block any nonspecific phage binding later in the
procedure, 400 mL 2% (w/v) bovine serum albumin (BSA) in PBS
was added to the wells, and incubation at room temperature
continued for 2 hours. The wells were rinsed again with PBS/
Tween before the addition of a 100-mL sample of phage-display
library containing 1 10
10 colony-forming units (cfus). Plates
were incubated overnight at 48C to allow the interaction of anti-
CaSR antibodies with peptides displayed on the surfaces of the
phage particles. The wells were washed extensively with PBS/
Tween to remove unbound phage. Bound phage then were
eluted with 150 mL 100 mM HCl (adjusted to pH 2.2 with solid
glycine) and neutralized with 9 mL 2 M Tris-HCl (pH 7.6). The
phage suspension was used subsequently to infect 2 mL of
exponentially growing E. coli XL1-Blue cells for 15 minutes at
room temperature. Aliquots of the infected cells then were
plated onto selective medium to allow the recovery of individual
bacterial clones for analysis.
To generate a phage-display library for a further round of
selection, the infected E. coli XL1-Blue cell culture was super-
infected with helper phage and phage precipitated and titred as
described earlier. This first-round library enriched in phage
displaying antibody-binding peptides then was used in a second
round of selective enrichment. In all, five rounds of biopanning
were undertaken.
For analysis, individual bacterial clones were cultured, and
phagemid DNA was prepared using a Wizard Minipreps DNA
Purification System (Promega). To confirm the presence of a
cDNAinsert,phagemidDNA(50-ngsamples)wassubjectedto36
cycles of polymerase chain reaction (PCR) amplification in a DNA
Thermal Cycler with primers 5’-GGTGGCGGCCGCAAATTC-3’ and
5’-GCCGCCAGCATTGACAGG-3’ (MWG Biotech, Munich, Ger-
many) using previously detailed reaction conditions.
(24) The
primers used flank the EcoRV cloning site in pComb3. The PCR
amplification products were analyzed by agarose gel electro-
phoresis and purified according to a Wizard PCR Preps DNA
Purification System (Promega). Sequencing with primer 5’-
GGTGGCGGCCGCAAATTC-3’ was carried using a BigDye Termi-
nator Version 3.1 Cycle Sequencing Kit (Applied Biosystems,
Foster City, CA, USA) and an ABI 3730 capillary sequencer
(Applied Biosystems). Insert DNA sequences were compared
with the full-length CaSR cDNA sequence using the BLAST
network service of the National Center for Biotechnology
Information (Bethesda, MD, USA).
Phage ELISA
For increased expression of phage-displayed CaSR peptides for
use in a phage ELISA, cDNA sequences encoding the CaSR
peptides of interest were subcloned into vector pComb8
(22)
using restriction enzymes XhoI (Promega) and SpeI (Promega)
employing standard subcloning protocols.
(24) All constructs were
verified by DNA sequencing, as detailed earlier.
Phage displaying CaSR peptides required for analysis in phage
ELISA then were prepared from individual bacterial clones as
describedearlierafterelectroporatingtheappropriatephagemid
DNA into E. coli XL1-Blue cells and superinfecting with helper
phage. Corning polystyrene 96-well microtiter plates were
coated with 100-mL aliquots of phage (10
10 cfus) in coating
buffer containing 1.5 mM Na2CO3 and 3.5 mM NaHCO3 (pH 9.2)
and incubated overnight at 48C. Helper phage were included in
each assay as a control for background antibody binding. Wells
were washed with PBS/0.1% (w/v) Tween 20, blocked with 3%
(w/v) BSA in PBS at room temperature for 1 hour, and then
washed with PBS/0.1% (w/v) Tween 20. Human sera were pre-
absorbedwith E.coli extract and helperphage andthentested in
phage ELISA at dilutions of 1:50. Animal anti-CaSR antibodies
wereanalyzed at a dilution of1:1000. Aliquots (100 mL) ofserum/
antibody were added to wells, and PBS was applied as a control.
The plates were incubated at room temperature for 2 hours and
then washed six times with PBS/0.1% (w/v) Tween 20. Aliquots
(100 mL) of antihuman (Sigma), antirabbit (Sigma). or antimouse
(Acris Antibodies) IgG alkaline phosphatase conjugate diluted
1:1000 in PBS/0.1% (w/v) Tween 20 were added to the wells for
1 hour at room temperature. After washing six times with PBS/
0.1% (w/v) Tween 20, 100 mL of alkaline phosphatase substrate
(Sigma Fast p-Nitrophenyl Phosphate Tablet Set, Sigma) were
applied to each well, and plates were incubated at room
temperature for 30 minutes. A LabSystems Integrated EIA
Management System (Life Sciences International, Hampshire,
UK) was used to read absorption of the wells at 405 nm.
All sera were tested in triplicate and the average OD405 value
taken. OD405 values were corrected for background reactivity to
helper phage to give an antibody (Ab) index. Each serum was
tested in at least three experiments, and the mean Ab index was
calculated. The upper limit of normal for each assay was
calculated using the mean Ab index þ 3 SD of the population of
20 healthy individuals. Any sample with an Ab index above the
upper limit of normal was designated as positive for antibody
reactivity to the phage-displayed CaSR peptide.
Synthetic peptides corresponding to amino acids 1–36, 41–69,
114–126, and 171–195 of CaSR were purchased from Severn
Biotech, Ltd. (Kidderminster, UK). In absorption experiments,
peptides were incubated with sera at 48C for 2 hours at 1 mg/mL
priortotestingtheserumsampleinphageELISA.Abindicesthen
were calculated as before. The percentage antibody binding was
determined as Ab index in presence of peptide/Ab index in
absence of peptide 100. Samples were tested in three
experiments, and the mean percentage antibody binding was
calculated.
Synthetic peptide ELISA
Synthetic peptides corresponding to amino acids 214–238, 344–
358, and 374–391 of CaSR were purchased from Severn Biotech,
Ltd. Corning polystyrene 96-well microtiter plates were coated
with 3 mg of peptide in coating buffer and incubated overnight
at 48C. Wells were washed with PBS/0.1% (w/v) Tween 20,
blocked with 3% (w/v) BSA in PBS at room temperature for
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sera were tested in peptide ELISA at dilutions of 1:50. Aliquots
(100 mL) of serum were added to wells, and PBS was applied as a
control. The plates were incubated at room temperature for 2
hours and then washed six times with PBS/0.1% (w/v) Tween 20.
Antibody binding was detected with alkaline phosphatase–
conjugated secondary antibody, as detailed earliar.
All sera were tested in triplicate, and the average OD405 value
was taken to give an Ab index. Each serum was tested in at least
three experiments, and the mean Ab index was calculated. The
upper limit of normal for each assay was calculated using
the mean Ab indexþ3 SD of the population of 10 healthy
individuals. Any sample with an Ab index above the upper limit
of normal was designated as positive for antibody reactivity to
the CaSR peptide.
Statistical analyses
The prevalence of antibody reactivity to phage-displayed and
synthetic CaSR peptides was compared between patient groups
and controls using Fisher’s exact test for 2 2 contingency
tables.Intra-andinterassayvariationswerecalculatedaspercent-
age coefficients of variation. Differences in antibody titers were
analyzed by the Wilcoxon matched-pairs test. P values < .05
(two-tailed) were regarded as significant in all tests.
Results
Construction of a CaSR peptide phage-display library
A library of randomly generated CaSR cDNA fragments was
constructed in the phage-display vector pComb3. The size of the
CaSR cDNA fragment library was 1.2 10
6 independent clones.
Amplification by PCR of phagemid DNA isolated from individual
bacterial clones demonstrated that the CaSR cDNA fragment
library was 100% recombinant, with insert size ranging from less
than 100 to 300 bp. The sequencing of 50 individual phagemid
DNA indicated that the library contained random CaSR cDNA
fragments with no bias for particular CaSR sequences.
Following amplification with helper phage, an initial phage-
display library of 5 10
11 cfus/mL was produced. In this library,
peptides that exactly represent CaSR amino acid sequences can
be displayed on the surfaces of phage particles, provided that
their encoding cDNA sequence is cloned in frame with the PelB
leader peptide and the gene III phage coat protein present in
pComb3 at the N- and C-terminals, respectively.
Biopanning of the phage-display CaSR peptide library
In order to enrich immunoreactive peptides recognized by anti-
CaSR antibodies, the CaSR peptide phage-display library was
immunoscreened in biopanning experiments with sera from 14
APS1 patients, 1 AHH patient, and 2 controls, as well as with anti-
CaSR antibodies as positive controls. Five rounds of biopanning
were carried out, and phagemid DNA from 16 to 20 bacterial
clones was analyzed by DNA sequencing to identify CaSR
peptides that had been selected during the enrichment process.
The results demonstrated that biopanning of sera from 12 of
14 (86%) APS1 patients and 1 AHH patient had enriched CaSR
peptides containing a CaSR amino acid consensus sequence
(Table 1). Nine of the 14 (64%) patients had enriched two
consensus peptides, and 3 of 14 (21%) had enriched one
consensus peptide (see Table 1). In all cases, the consensus
peptide sequence was in frame with respect to both the PelB
leader peptide and the gene III coat protein, indicating that the
correct phage-surface expression of the encoded CaSR peptides
could occur. In biopanning experiments with sera from 2
controls, no identifiable CaSR consensus sequence was enriched.
This also was the case for 2 of 14 of the APS1 patient sera
analyzed (see Table 1). In each case, phagemid from the fifth
round of biopanning carried CaSR cDNA fragment inserts that
would not be expressed correctly to give CaSR peptides on the
surfaces of phage particles. The results also demonstrated that
animal anti-CaSR polyclonal and monoclonal antibodies had
enriched amino acid consensus sequences corresponding to the
whole or part of the peptide against which they were raised (see
Table 1).
Comparison of the consensus peptides enriched by each of
the APS1 patient sera and the single AHH patient serum enabled
identification of consensus sequences enriched by different
patients (Table 2). Three consensus peptides were determined,
CaSR amino acid residues 41–69, 114–126, and 171–195, these
potentially representing separate antibody-binding sites on the
receptor.
Phage ELISA with patient and control sera
To confirm immunoreactivity to phage-displayed CaSR peptides
identified in biopanning experiments, sera from 14 APS1
patients, 1 AHH patient (3 separate serum samples), and 20
healthy controls were tested in a phage ELISA format. All CaSR
peptides used in phage ELISA were expressed in pComb8
following subcloning of the relevant cDNA fragment in frame
with the PelB leader peptide and the gene VIII coat protein
present in the vector. The phage used expressed either CaSR
peptides 41–74, 110–130, or 169–198 because these encom-
passed the putative CaSR epitope consensus sequences 41–69,
114–126, and 171–195, respectively (Table 2). All sera also were
analyzedinphage ELISAagainstpeptides1–36and210–241that
contained the epitopes for anti-CaSR polyclonal and monoclonal
antibodies, respectively. Anti-CaSR antibody and anti-CaSR mAb
were used as positive controls in phage ELISA against phage
displaying either peptide 1–36 or peptide 210–241, respectively.
An antibody index was calculated for each serum, and the upper
limit of normal for each phage ELISA was determined. Any serum
sample with an antibody index above the upper limit of normal
was designated as positive for antibody reactivity to the phage-
displayed CaSR peptide.
The antibody indices for APS1 and AHH (3 separate serum
samples)patientsaswellascontrolseraareshowninFig.1.Intra-
and interassay variations for each sample were no more than
12% and 15%, respectively. All control sera were negative for
antibody reactivity against all the phage-displayed CaSR
peptides tested. The anti-CaSR polyclonal and monoclonal
antibodies were positive only in phage ELISA against phage-
displayed peptides 1–36 and 210–241, respectively.
OftheAPS1patientseraanalyzed,12of14(86%)werepositive
for antibodies against atleastone CaSRpeptide (Table3). Nine of
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CaSR peptides, and 3 of 14 (21%) were positive against one (see
Table 3). None of the APS1 sera analyzed was positive for
antibodies against peptides 1–36 and 210–241 (see Table 3). The
two APS1 patient serum samples that failed to react against any
phage-displayed CaSR peptides in phage ELISA were those that
also failed to enrich specific sequences in biopanning experi-
ments. Antibodies against CaSR peptides 41–74, 110–130, and
169–198 were significantly more prevalent in the APS1 patient
group compared with controls (P<.0001, P¼.0072 and
P¼.0216, respectively; see Table 3). The three separate serum
samplesfrom the AHH patient reacted only against CaSRpeptide
41–74.
To confirm antibody reactivity detected in phage ELISAs, APS1
patient sera, as appropriate, were incubated with and without
synthetic peptides (41–69, 114–126, and 171–195) prior to
testing in phage ELISA experiments. The CaSR peptide 1–36 was
used as a control in all experiments. Antibody indices and the
mean percentage antibody binding were calculated for each
sample.
Table 2. CaSR Consensus Peptide Sequences Enriched by Different APS1 Patient Sera
Consensus peptide (amino acid
residues of CaSR
a)
Number of APS1 patient
sera enriching consensus peptide (%)
APS1 patient serum
samples enriching consensus peptide
c
HFGVAAKDQDLKSRPESVECIRYNFRGFR (41–69)
b 12/14 (86) 2–7, 9–11, 13–15
FVAQNKIDSLNLD (114–126) 5/14 (36) 2–4, 7, 15
SRLLSNKNQFKSFLRTIPNDEHQAT (171–195) 4/14 (29) 6, 10, 13, 14
aAmino acid residues are numbered according to CaSR peptide sequence with the ATG initiation codon as residue number 1.
bThe 41–69 peptide sequence was enriched by a serum sample from the single AHH patient.
cNumbers refer to individual APS1 patients.
Table 1. CaSR Consensus Peptide Sequences Enriched in Biopanning Experiments
Sample used in
biopanning experiments
a CaSR consensus peptide sequences
b
Amino acid
residues of CaSR
c
Number of clones with
consensus sequence (%)
APS1-2 AQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGFRWL 26–71 9/20 (45)
TVSKALAEATLSFVAQNKIDSLNLDEFCNCSE 103–133 3/20 (15)
APS1-3 HFGVAAKDQDLKSRPESVECIRYNFRGFRWL 41–71 8/16 (50)
KALAEATLSFVAQNKIDSLNLDEFCN 106–130 2/16 (13)
APS1-4 HFGVAAKDQDLKSRPESVECIRYNFRGFRWL 41-71 5/20 (25)
FVAQNKIDSLNLD 114–126 3/20 (15)
APS1-5 LGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGFR 34–69 3/20 (15)
APS1-6 AQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGFRWL 26-71 9/20 (45)
SRLLSNKNQFKSFLRTIPNDEHQAT 171–195 2/20 (10)
APS1-7 GDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGFR 30–69 8/20 (40)
TVSKALAEATLSFVAQNKIDSLNLDEFCNCSE 103–133 3/20 (15)
APS1-8 No consensus peptide sequence defined ——
APS1-9 QKKGDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGFRWL 27–71 2/20 (10)
APS1-10 AQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGFRWL 26–71 10/20 (50)
SRLLSNKNQFKSFLRTIPNDEHQAT 171–195 3/20 (15)
APS1-11 QKKGDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGFRWL 27–71 2/20 (10)
APS1-12 No consensus peptide sequence defined ——
APS1-13 HFGVAAKDQDLKSRPESVECIRYNFRGFRWL 41–71 10/20 (50)
SRLLSNKNQFKSFLRTIPNDEHQAT 171–195 3/20 (15)
APS1-14 HFGVAAKDQDLKSRPESVECIRYNFRGFRWL 41–71 8/20 (40)
SRLLSNKNQFKSFLRTIPNDEHQAT 171–195 2/20 (10)
APS1-15 QKKGDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGFRWL 27–71 3/20 (15)
TVSKALAEATLSFVAQNKIDSLNLDEFCNCSE 103–133 3/20 (15)
AHH HFGVAAKDQDLKSRPESVECIRYNFRGFRWL 41–71 9/20 (45)
Anti-CaSR Ab
d YGPDQRAQ 20–27 10/20 (50)
Anti-CaSR mAb
e ADDDYGRPGIEKFREEAEERDICI 214–237 10/20 (50)
aAPS1 samples 2 to 15 are sera from APS1 patients; AHH sample is a serum sample from the single AHH patient.
bPeptidesequencesenrichedbybiopanningofthephage-displayCaSRpeptidelibrarywithAPS1andAHHpatientseraandanimalanti-CaSRantibodies.
cAmino acid residues are numbered according to the CaSR peptide sequence with the ATG initiation codon as residue number 1.
dPolyclonal CaSR antibody.
eMonoclonal CaSR antibody.
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peptide 41–69 was reduced to 30% 4% for sera from APS1
patients 2 to 7, 9 to 11, and 13 to 15, as well as 26% 5% for the
three serum samples from the AHH patient. In phage ELISAs 110
to130inthepresenceofpeptide114–126,antibodybindingwas
reduced to 28% 7% for sera from APS1 patients 2, 3, 4, 7, and
15. In phage ELISAs 169 to 198 in the presence of peptide 171–
195, antibody binding was reduced to 30% 7% for sera from
APS1 patients 6, 10, 13,and 14. No inhibition of antibody binding
was apparent in the presence of peptide 1–36 in any of the
ELISAs.
Analysis of CaSR epitopes for patient
anti-CaSR antibodies
Analysis of the results from phage ELISAs suggested that a major
CaSR epitope was localized in the N-terminal extracellular
domain of the CaSR at amino acid residues 41–69 with antibody
reactivity demonstrated in 12 of 12 (100%) of APS1 patients and
the single patient with AHH (Table 4). Minor epitopes were
located in amino acid domains 114–126 and 171–195, with
antibodyreactivityshownin5of12(42%)and4of12(33%)APS1
patients, respectively (see Table 4). Epitopes in amino acid
sequences representing the remainder of the extracellular
region, the membrane-spanning segment, and the intracellular
domain were not identified. Multiple binding sites on CaSR were
apparent for antibodies in 9 of 12 (75%) patients, and one
binding site was identified in 3 of 12 (25%) patients.
Synthetic peptide ELISAs with patient and control sera
To analyze immunoreactivity to CaSR synthetic peptides 41–69,
114–126, 214–238, 344–358, and 374–391, sera from 14 APS1
patients, 1 AHH patient (3 separate serum samples), and 10
healthy controls were tested in an ELISA format. An antibody
index was calculated for each serum, and the upper limit of
normal for each peptide ELISA was determined. Any serum
sample with an antibody index above the upper limit of normal
was designated as positive for antibody reactivity to the CaSR
peptide. The anitbody indices for APS1 and AHH (3 separate
serum samples) patients as well as control sera are shown in
Fig. 2. Intra- and interassay variations for each sample were no
more than 10% and 12%, respectively.
Allcontrolserawerenegativeforantibodyreactivityagainstall
the CaSR peptides tested. The three separate serum samples
from the AHH patient reacted only against CaSR peptide 41–69.
Of the APS1 patient sera analyzed, all were negative for antibody
reactivity to peptides 214–238, 344–358, and 374–391. Antibody
reactivity was evident against peptides 41–69 and 114–126 in
12 (patients 2 to 7, 9 to 11, and 13 to 15) and 5 (patients 2 to 4,
7, and 15), respectively, of the APS1 patient sera tested.
The immunoreactivity of the APS1 patient sera in the peptide
ELISAa confirmed that demonstrated in the phage ELISA
experiments.
Discussion
Previously, we identified anti-CaSR antibodies in patients with
APS1 using immunoprecipitation assays.
(16) The aim of this study
was to define the epitope specificity of patient anti-CaSR
Table 3. Results of Phage ELISA
Peptide sequence
displayed on phage
a
Number of APS1 patient sera
positive for antibody in
phage ELISA (%)
Number of control sera
positive for antibody
reactivity in phage
ELISA (%) P value
b
APS1 patient samples
with antibody reactivity
to peptide
c
41–74 12/14 (86) 0/20 (0) <0.0001 2–7, 9–11, 13–15
110–130 5/14 (36) 0/20 (0) 0.0072 2–4, 7, 15
169–198 4/14 (29) 0/20 (0) 0.0216 6, 10, 13, 14
1–36 0/14 (0) 0/20 (0) ——
210–241 0/14 (0) 0/20 (0) ——
aAmino acid residues are numbered according to CaSR peptide sequence with the ATG initiation codon as residue number 1.
bTheprevalenceofantibodyreactivitytophage-displayedCaSRpeptideswascomparedbetweenAPS1patientsandcontrolsusingFisher’sexacttestfor
2 2 contingency tables. P values < .05 (two-tailed) were regarded as significant.
cNumbers refer to individual APS1 patients.
Fig. 1. Phage ELISAs with patient and control sera. Patient and control
sera were analyzed for antibody binding in phage ELISAs, as detailed in
Materials and Methods. The Ab indices are shown for APS1 (n¼14) and
AHH (n¼3) patient sera and for control (C) (n¼20) serum samples
analyzed in phage ELISAs against phage-displaying CaSR peptides 1–36,
41–74, 110–130, 169–198, and 210–241.
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employed successfully in identifying autoantigenic epitopes in
several autoimmune diseases.
(25–27)
In the present study, anti-CaSR antibody-binding sites were
mapped to amino acid residues 41–69, 114–126, and 171–195 at
the N-terminal of the extracellular domain of the receptor, these
being previously unreported. The major autoepitope appeared
to be localized in amino acid sequence 41–69 of the CaSR, with
antibody reactivity demonstrated in 12 of 12 (100%) of APS1
patients and the single AHH patient available for study. Minor
epitopes were located in amino acid domains 114–126 and 171–
195, with antibody reactivity shown in 5 of 12 (42%) and 4 of 12
(33%) of APS1 patients, respectively. Epitopes in the amino acid
sequences representing the remainder of the extracellular
region, the membrane spanning segment, and the intracellular
domain of the CaSR were not identified. The results also indicate
that the humoral response to the CaSR in APS1 is heterogeneous
in nature, with several patients exhibiting antibodies to more
than one CaSR epitope.
Overall, our findings are in agreement with earlier studies that
have suggested that antigenic epitopes for human anti-CaSR
antibodies are localized to the extracellular domain of the
receptor.
(14–16) However, specific epitopes at amino acids 214–
236, 374–391, and 344–358 in the extracellular domain, which
had been reported previously for patient antibodies targeting
the CaSR,
(18–20) were not identified in the present study. Similar
results to ours have been reported recently for an AHH patient
with anti-CaSR antibodies: No antibody reactivity to CaSR
peptides 214–236, 374–391, and 344–358 was apparent in this
individual.
(21) In this study, the CaSR epitopes mapped using
phage display were confirmed in ELISA experiments using
synthetic peptides, indicating that both techniques can identify
relevant antibody-binding sites. Variations between the epitopes
identified in this study and those reported previously more likely
may reflect differences between the individual patients who
were included.
Interestingly, the major epitope (amino acids 41–69) demon-
strated in this study overlaps the CaSR loop 1 domain (amino
acids 50–59), which, if deleted, reduces receptor activation.
(28,29)
Binding of antibody to this epitope, therefore, might modulate
the function of the receptor. Our data do not explain why the
presence of autoantibodies to this major epitope should be
associated with hypocalcemia in APS1 patients and hypercalce-
mia in the case of AHH. Perhaps binding of the antibody to
separate regions within this epitope can exert diametrically
opposite effects on the activity of the CaSR. It will be of
considerable interest to study additional patients with AHH.
However, such patients are extremely rare, and the patient
studied here represents only the seventh identified to date with
this condition.
(19–21)
The minor epitope (amino acids 114–126) overlaps the CaSR
loop 2 domain (amino acids 117–136). Deletion of this region or
point mutations present in this region in the human disease
autosomal dominant hypoparathyroidism (ADH) increase the
sensitivity of the CaSR to Ca
2þ.
(28,29) It has been postulated,
therefore,thatloop2mayplayakeyroleinmaintainingtheCaSR
in an inactive state in part through the two disulfide linkages
involving cysteine residues C129 and C131. Notably, mutations
of these two amino acids are a cause of ADH in at least
five families (see Calcium-Sensing Receptor Database at
www.casrdb.mcgill.ca). In view of the foregoing, antibody
binding to epitopes within loop 2 could either activate or
inhibit the receptor depending on whether binding of the
antibody favored the active or inactive conformation(s),
respectively.
The minor epitope encompassing amino acid residues 171–
195 is of particular interest because molecular modeling
combined with site-directed mutagenesis has suggested that
several of these residues are part of a binding site for extra-
cellular calcium that lies in the crevice between the two lobes of
each receptor monomer.
(30,31) The residues that have been
predicted to participate incalcium binding are amino acids S147,
S170, D190, Y218, and E297. In addition, residues 169–171 are
thought to be part of a binding site for amino acids that serve as
allostericactivatorsofthereceptor,
(32)particularlyphenylalanine,
tyrosine, and other aromatics. It is easy to conceive of how
binding of an antibody to this region of the receptor could
Fig. 2. Synthetic peptide ELISAs with patient and control sera. Patient
and control sera were analyzed for antibody binding to synthetic pep-
tides in an ELISA format, as detailed in Materials and Methods. The Ab
indices are shown for APS1 (n¼14) and AHH (n¼3) patient sera and for
control(C)(n¼10)serum samplesanalyzedin ELISAexperimentsagainst
synthetic CaSR peptides 41–69, 114–126, 214–238, 344–358, and 374–
391.
Table 4. Epitope Specificities of APS1 Patient Anti-CaSR
Antibodies
CaSR
epitope
a
Number of APS1
patients with anti-CaSR
antibodies recognizing
epitope (%)
APS1 patients
with anti-CaSR
antibodies
recognizing epitope
c
41–69
b 12/12 (100) 2–7, 9–11, 13–15
114–126 5/12 (41) 2–4, 7, 15
171–195 4/12 (33) 6, 10, 13, 14
aAmino acid residues are numbered according to CaSR peptide
sequence with the ATG initiation codon as residue number 1.
bThe 41–69 epitope was recognized by anti-CaSR antibodies in the
single AHH patient studied.
cNumbers refer to individual APS1 patients.
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and associated changes in the conformation of the CaSR’s
extracellular domain.
Since patient sera were used in this study to identify CaSR
epitopes, it is not possible to discriminate between a single anti-
CaSR antibody targeted at an epitope and a set of closely related
anti-CaSR antibodies directed at the same epitope. To gain
information on the epitope specificity of a particular autoanti-
body usually requires the production of human monoclonal
antibodies from the patient. Indeed, monoclonal antibodies
isolated from individualswithtype1diabetes mellitushavebeen
employed successfully in identifying the antibody-binding sites
on glutamic acid decarboxylase.
(33) In future work, the isolation
of anti-CaSR monoclonal antibodies from APS1 patients will
allow a more complete and detailed analysis of the array of anti-
CaSR antibodies and the epitopes they recognize.
To summarise, the present study is the first to define specific
epitopesontheCaSRforanti-CaSR antibodiesinpatientswiththe
APS1,aswellasidentifyingantibody-bindingsitesonthereceptor
inacaseofAHH.Inaddition,wehavedemonstratedthesuccessful
useofphage-displaytechnologyinthediscoveryofCaSRepitopes
for human antibodies that target this molecule. This may be of
interest to other researchers who wish to define the binding sites
forhuman anti-CaSR antibodies found in other diseases as well as
monoclonal antibodies raised against the receptor.
(34)
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